These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 30100755)
1. PRAF2 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Wang CH; Liu LL; Liao DZ; Zhang MF; Fu J; Lu SX; Chen SL; Wang H; Cai SH; Zhang CZ; Zhang HZ; Yun JP Cancer Manag Res; 2018; 10():2241-2248. PubMed ID: 30100755 [TBL] [Abstract][Full Text] [Related]
2. PRAF2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells. Wang Y; Zhao Z; Jiao W; Yin Z; Zhao W; Bo H; Bi Z; Dong B; Chen B; Wang Z Exp Ther Med; 2022 Dec; 24(6):738. PubMed ID: 36478884 [TBL] [Abstract][Full Text] [Related]
3. PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma. Qian Z; Wei B; Zhou Y; Wang Q; Wang J; Sun Y; Gao Y; Chen X BMC Cancer; 2019 Jun; 19(1):585. PubMed ID: 31200670 [TBL] [Abstract][Full Text] [Related]
4. LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Wang CH; Li M; Liu LL; Zhou RY; Fu J; Zhang CZ; Yun JP Oncotarget; 2015 Dec; 6(39):42118-29. PubMed ID: 26517349 [TBL] [Abstract][Full Text] [Related]
5. PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma. Yco LP; Geerts D; Koster J; Bachmann AS Int J Oncol; 2013 Apr; 42(4):1408-16. PubMed ID: 23440329 [TBL] [Abstract][Full Text] [Related]
6. Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: Influence on cell survival and migration. Borsics T; Lundberg E; Geerts D; Koomoa DL; Koster J; Wester K; Bachmann AS Cancer Sci; 2010 Jul; 101(7):1624-31. PubMed ID: 20412121 [TBL] [Abstract][Full Text] [Related]
7. Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Geerts D; Wallick CJ; Koomoa DL; Koster J; Versteeg R; Go RC; Bachmann AS Clin Cancer Res; 2007 Nov; 13(21):6312-9. PubMed ID: 17975142 [TBL] [Abstract][Full Text] [Related]
8. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591 [TBL] [Abstract][Full Text] [Related]
9. High expression of Golgi phosphoprotein-3 is associated with poor survival in patients with hepatocellular carcinoma. Hu GS; Li YQ; Yang YM; Shi W; Liao AJ; Yao YH; Zeng B; Yuan J Tumour Biol; 2014 Sep; 35(9):8625-32. PubMed ID: 24867097 [TBL] [Abstract][Full Text] [Related]
10. Increased Expression of CAP2 Indicates Poor Prognosis in Hepatocellular Carcinoma. Fu J; Li M; Wu DC; Liu LL; Chen SL; Yun JP Transl Oncol; 2015 Oct; 8(5):400-406. PubMed ID: 26500030 [TBL] [Abstract][Full Text] [Related]
11. HEY2, a target of miR-137, indicates poor outcomes and promotes cell proliferation and migration in hepatocellular carcinoma. Wu DC; Zhang MF; Su SG; Fang HY; Wang XH; He D; Xie YY; Liu XH Oncotarget; 2016 Jun; 7(25):38052-38063. PubMed ID: 27191260 [TBL] [Abstract][Full Text] [Related]
12. The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma. Pan JJ; Ge YS; Xu GL; Jia WD; Liu WF; Li JS; Liu WB J Cancer Res Clin Oncol; 2013 Jun; 139(6):1043-54. PubMed ID: 23525579 [TBL] [Abstract][Full Text] [Related]
13. CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma. Yang YF; Pan YH; Tian QH; Wu DC; Su SG Transl Oncol; 2018 Oct; 11(5):1110-1118. PubMed ID: 30031230 [TBL] [Abstract][Full Text] [Related]
14. High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. Liu F; Zhang Y; Peng Z; Gao H; Xu L; Chen M J Transl Med; 2012 Jul; 10():135. PubMed ID: 22747650 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of heterogeneous ribonucleoprotein A1 expression and inflammatory indicators for patients with surgically resected hepatocellular carcinoma: Perspectives from a high occurrence area of hepatocellular carcinoma in China. Ke R; Lv L; Li J; Zhang X; Yang F; Zhang K; Jiang Y Oncol Lett; 2018 Sep; 16(3):3746-3756. PubMed ID: 30127985 [TBL] [Abstract][Full Text] [Related]
16. Low expression of organic anion-transporting polypeptide 1B3 predicts a poor prognosis in hepatocellular carcinoma. Chen S; Li K; Jiang J; Wang X; Chai Y; Zhang C; Deng Q; Shuai L; Feng K; Ma K; Zhang L World J Surg Oncol; 2020 Jun; 18(1):127. PubMed ID: 32534581 [TBL] [Abstract][Full Text] [Related]
17. Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. Geng M; Cao YC; Chen YJ; Jiang H; Bi LQ; Liu XH World J Gastroenterol; 2012 Mar; 18(12):1328-38. PubMed ID: 22493546 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma. Cui J; Yu Y; Lu GF; Liu C; Liu X; Xu YX; Zheng PY Tumour Biol; 2013 Jun; 34(3):1913-8. PubMed ID: 23516026 [TBL] [Abstract][Full Text] [Related]
19. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma. Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125 [TBL] [Abstract][Full Text] [Related]
20. NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis. Liu LL; Zhang MF; Pan YH; Yun JP; Zhang CZ Tumour Biol; 2014 Mar; 35(3):1763-74. PubMed ID: 24563371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]